Sematid 3 mg (Tablet)
Unit Price: ৳ 800.00 (1 x 10: ৳ 8,000.00)
Strip Price: ৳ 8,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Semaglutide |
| Company | Acme laboratories ltd |
| Also available as |
Title and Categories
- Sematid Tablet
- Pharmaceuticals
- Diabetes Medication
- Weight Management
- GLP-1 Receptor Agonist
Indications
- Improves glycemic control in adults with type 2 diabetes mellitus
- Reduces the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
- Adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with obesity or overweight
Pharmacology
- GLP-1 analogue with 94% sequence as same as human GLP-1
- Stimulates insulin secretion
- Lowers glucagon secretion
- Reduces blood glucose in a glucose-dependent manner
- Reduces body weight and body fat mass by reducing appetite
Dosage and Administration
- Take at least 30 minutes before the first food, beverage, or other oral medications of the day with no more than 4 ounces (118 ml) of plain water only
- Starter Dose: 3 mg once daily for 30 days
- Maintenance Dose: 7 mg once daily after 30 days on the 3 mg dose
- 14 mg once daily for additional glycemic control if needed
- Injection: Starting dose of 0.25 mg once weekly, maintenance dose varies for glycemic control
- Switching patients between injection and tablet
Interaction
- Delays gastric emptying
- Potential impact on the rate of absorption of concomitantly administered oral medicinal products
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
Side Effects
- Hypoglycemia when used with insulin or sulfonylurea
- Gastrointestinal disorders
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Constipation
- Allergic reaction
- Injection site reaction
- Lipodystrophy
- Pruritus
- Rash
Pregnancy and Lactation
- Should not be used during pregnancy
- Discontinue at least 2 months before planned pregnancy
- Avoid use during breastfeeding
Precautions and Warnings
- Avoid in type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis
- Discontinue promptly if pancreatitis is suspected
- Monitor patients with diabetic retinopathy
Use in Special Populations
- Safety and efficacy in children and adolescents below 18 years have not yet been established
- No dose adjustment based on age
- No dose adjustment for patients with mild moderate or severe renal impairment
- Not recommended for use in patients with end-stage renal disease
- No dose adjustment for patients with hepatic impairment
- Caution in treating patients with hepatic impairment
Overdose Effects
- Reported overdose reactions
- Nausea as the most commonly reported adverse reaction
- No specific antidote for overdose
- Dose adjustment when combined with other therapies
- Guidance on missed dose administration
Therapeutic Class
- GLP-1 receptor agonists
Storage Conditions
- Store at 2 °C to 8 °C in a refrigerator
- Do not freeze
- Keep out of reach of children